Showing results (231-240 of 588) with videos related to
Sort By:
Pageof 59
JAMA Internal Medicine|June 3, 2014
5α-Reductase inhibitors and risk of high-grade or lethal prostate cancerMark A Preston, Kathryn M Wilson, Sarah C Markt, et al.Cancer & Metabolism|August 7, 2024
The polyunsaturated fatty acid docosahexaenoic affects mitochondrial function in prostate cancer cellsGuilherme Henrique Tamarindo, Caroline Fidalgo Ribeiro, Alana Della Torre Silva, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2021
Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR TrialThomas Denize, Subrina Farah, Alessia Cimadamore, et al.Plos Genetics|September 27, 2018
Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinomaLana Hamieh, Toni K Choueiri, Barbara Ogórek, et al.Cancer Discovery|August 17, 2012
Identification of luminal breast cancers that establish a tumor-supportive macroenvironment defined by proangiogenic platelets and bone marrow-derived cellsHanna S Kuznetsov, Timothy Marsh, Beth A Markens, et al.Genome Biology|August 24, 2016
Comprehensive analyses of tumor immunity: implications for cancer immunotherapyBo Li, Eric Severson, Jean-Christophe Pignon, et al.Nature Medicine|January 9, 2018
Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanismsMarco Bezzi, Nina Seitzer, Tomoki Ishikawa, et al.BJU International|November 8, 2008
P-cadherin as a prognostic indicator and a modulator of migratory behaviour in bladder carcinoma cellsJessica A Mandeville, Brasil Silva Neto, Alex J Vanni, et al.BJU International|January 26, 2016
Risk of prostate cancer-specific death in men with baseline metabolic aberrations treated with androgen deprivation therapy for biochemical recurrenceSarah M Rudman, Kathryn P Gray, Julie L Batista, et al.Nature|September 6, 2016
On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer modelsHyejin Cho, Xinlin Du, James P Rizzi, et al.Pageof 59